Occasional reviews

Treatment of adult respiratory distress syndrome: plea for rescue therapy of the alveolar epithelium

Yves Berthiaume, Olivier Lesur, André Dagenais

Although much has been learned about the mechanisms leading to acute lung injury, mortality—which is mainly related to sepsis or associated non-pulmonary organ dysfunction—remains high (around 50%) in patients with adult respiratory distress syndrome (ARDS). Many new therapeutic approaches aiming to control the inflammatory response accompanying ARDS have been evaluated. However, these treatments have had no impact on the mortality stemming from the disease. The lack of success with these new interventions is probably multifactorial. One possible explanation is that the appropriate patient population had not been enrolled for study. In this regard, it is also probably unrealistic to hope that a single treatment will modify the evolution of all ARDS patients who represent a heterogeneous population with very different severities of lung injury. Thus, it is unlikely that the efficacious treatment of patients with mild lung injury will be as efficient in patients with severe lung injury.

Most of the treatments tested recently were targeted to control the inflammatory response. Although the development of lung injury is mainly dependent on aggression of endothelial cells by inflammatory cells, its severity and recovery also depend on epithelial cell function. In fact, the predominant pathological finding in acute lung injury is diffuse alveolar epithelial damage. Furthermore, physiologically it has been shown that the structure and function of the alveolar epithelium are important determinants of lung injury. Finally, the alveolar epithelium is also the site of alveolar fluid reabsorption and plays a major role in the development of lung fibrosis associated with ARDS. Treatments aimed at improving epithelial function might therefore become one of the key elements to accelerate recovery and decrease the mortality of patients with ARDS.

In this review we will emphasise the importance of modulating two of the many functions of the alveolar epithelium which we consider to be strategically necessary for quicker recovery from ARDS. After reviewing the characteristics of ARDS lesions, we will determine how we can stimulate the alveolar epithelium to increase oedema clearance and hasten epithelial repair.

The alveolar epithelium as a target of lung injury

Pathological observations of acute lung injury derive mainly from the analysis of necropsy material from patients who died of ARDS. By definition, these studies were done on subjects with severe lung injury and might not be representative of the pathological lesions present in the overall population of patients with acute lung injury. However, from these studies we can identify the different stages of the pathological process.

In the acute stage, corresponding to the first few days (<7) after the onset of injury, we mainly observe an exudative process characterised by extensive epithelial and endothelial barrier damage, resulting in the flooding of alveolar air spaces with proteinaceous liquid, inflammatory cells, and fibrin. Hyaline membranes are also seen in the alveolar spaces, especially at the end of this stage. This pathological stage is often categorised as diffuse alveolar damage. As the name suggests, the most conspicuous structure which is damaged is the alveolar epithelium—more precisely, the alveolar type I cells—which seem more sensitive to injury than alveolar type II cells. Endothelial cell injury is subtle and seems relatively minor to explain the rapid and continuous escape of protein-rich fluid from the microcirculation. Why there is such a disparate appearance of lesions between epithelial and endothelial cells is still a mystery, but one hypothesis is that the repair phase of endothelial cells is much more rapid than for epithelial cells. This also suggests that the alveolar epithelium may need some help to hasten the recovery phase from diffuse alveolar damage.

The second more chronic stage of acute lung injury (>7 days) is marked by its variability. In certain patients there is, in fact, rapid reabsorption of alveolar oedema fluid and repair of the injured region of the alveolar epithelium, followed by clinical recovery from respiratory failure. However, in a number of patients alveolar oedema persists and we notice the organisation of hyaline membranes and gradual appearance of intra-alveolar fibrosis.
The alveolar epithelium is a key element in the process of oedema clearance (fig 1). In fact, the alveolar epithelial barrier is not only a tight epithelium but it is also actively involved in the transport of ions and solutes. Three different experimental approaches have led to demonstrations of active ion transport in the alveolar region of the lung.

The first experimental strategy involved a model of alveolar flooding where autologous serum or an isotonic fluid containing trace amounts of albumin was instilled in the air spaces of the lung. Fluid clearance was then measured by determining the amount of excess water in the experimental lung compared with a control lung using a modified gravimetric method or by quantifying over time changes in the concentration of a non-permeable molecule (such as albumin) instilled into the lung with the fluid. With such an experimental approach it was established that liquid clearance was faster than protein clearance, so that the solution remaining in the air spaces became more concentrated as the liquid was removed. Since water clearance in the face of rising osmotic pressure could not be explained by changes in hydrostatic or osmotic forces across the alveolar epithelium, it was proposed that active transport of ions could be responsible (fig 1). This liquid clearance with rising protein concentration has been seen in the lungs of many species such as sheep, dogs, rats, and rabbits as well as humans. Although initially it was postulated that liquid reabsorption was occurring in the alveolar region only because it represented the largest surface area for reabsorption, recent experimental data have delivered new evidence to support such an hypothesis. Using alveolar micropuncture, Berthiaume et al were the first to show that the increase in protein concentration is identical in a sample of airway fluid taken from the distal airways and the alveolar micropuncture sample. This clearly suggests that liquid absorption occurs in the alveolar region. More recently Ballard et al used fluorocarbon to trap the instilled liquid in the very distal portion of the lung, mainly the alveolar region. With this model they could show that there is significant liquid absorption, again suggesting that liquid absorption occurs in very distal airways, probably in the alveolar region.

Although these data indicate active ion transport in the distal airways, further support of this hypothesis has come from experiments where lung liquid clearance was studied in the presence of inhibitors of ion transport. Ouabain, a Na+–K+–ATPase inhibitor, significantly decreased Na+ transport and fluid absorption in isolated lungs, suggesting that suppression of transepithelial ion transport is important in the process (fig 1). The presence of an active ion transport mechanism was further confirmed by Serikov et al who studied the effect of temperature on alveolar lung liquid clearance in isolated perfused goat lungs. In four hours they saw a 26% increase in protein concentration over baseline, similar to the result observed in sheep. However, when the temperature of the perfusate was decreased to 18°C there was no change in alveolar protein concentration, indicating that alveolar liquid clearance was temperature-independent.

**Figure 1** Schematic representation of the major pathways for ion and water transport involved in oedema clearance in the normal lung. The mechanisms that could explain how beta adrenergic agonists can increase the activity or expression of Na+ transport proteins are also illustrated.
clearance had been inhibited. These results confirmed that liquid clearance is not dependent so much on passive diffusion as it is on an active transport process.

Much experimental evidence suggests that active Na+ transport is the dominant ion transport mechanism involved in this process. Amiloride, a drug well known to interfere with Na+ transport,30 decreases lung liquid clearance by 40% to 75% in different species (fig 1).23–25 28 32 The potential role of Na+ in this process is also confirmed by the fact that, not only is liquid reabsorption inhibited by amiloride, but unidirectional Na+ movement from alveoli to the circulation is also suppressed by amiloride.26 27 Finally, the relationship between lung liquid clearance and Na+ transport is further established by the demonstration that, when Na+ is replaced by choline in the alveolar instillate, there is complete inhibition of fluid reabsorption.26 33

The cellular mechanism responsible for this vectorial transport of Na+ from alveoli to the interstitium has been better defined recently. Firstly, the alveolar type II cell is believed to be the principal cell involved in this process since it has a greater density of Na+-K+-ATPase than the alveolar type I cell and it has been shown to be involved actively in Na+ transport in vitro.39 Na+ enters the cell by the amiloride sensitive Na+ channel (ENaC) or by other cationic channels35 located at the apical surface and is extruded by Na+-K+ATPase located at the basolateral surface (fig 1).36 Recent experimental data have allowed us to define better the structure and function of the major system involved in this transepithelial transport.

The amiloride sensitive Na+ channel is the first constituent of the Na+ transport system. It has been cloned recently37–40 and consists of three subunits, α, β and γ ENaC, which are able to reconstitute a functional channel.38 In situ hybridisation and immunohistochemical staining have shown that the ENaC subunits are expressed along the epithelium of the respiratory system43–45 and are detected in alveolar type II cells.44 The physiological role of αENaC in the lung has been demonstrated in a mouse model where the αENaC gene was deleted by targeting a transgene by homologous recombination.46 Unable to clear liquid from their lungs, these mice die shortly after birth.46

ENaC activity and expression are regulated by a complex control system. The second messenger cAMP is thought to increase the activity of the channel (fig 1).47 Although the augmented activity of the channel is assumed to result from protein kinase A (PKA) activation and a specific phosphorylation event, it is still unclear if this involves direct phosphorylation of the channel or the phosphorylation of other proteins associated with the channel.48 The second hypothesis is more likely since PKA could increase channel activity in lipid bilayers only in the presence of actin,49 and the amino acid sequences of the three subunits contain no conserved intracellular PKA sites.50 Other physiological mechanisms have been shown to be involved in the modulation of ENaC.

Recent experimental data suggest that channel activity is also dependent on channel stability at the plasma membrane, a process regulated by ubiquitination.40 ENaC function is then dependent not only on direct modulation of channel activity but also on channel degradation or stability in the membrane. The increase in Na+ transport could also be associated with an increase in channel gene expression (fig 1). Around birth there is a transient rise in ENaC expression40 41 at a time when liquid reabsorption in the lung is enhanced. The two major hormones that are thought to modulate the ENaC expression in the lung are catecholamines52 and steroids.53 54

Besides ENaC, a multitude of other cation channels that could be involved in Na+ transport have been identified in alveolar type II cells.55 One of these channels, the non-selective cation channel, has been identified on both fetal and adult alveolar type II cells.56 The activity of this channel can be stimulated by β adrenergic agonists57 and can be inhibited by amiloride,58 59 suggesting that it could be involved in Na+ transport across the alveolar epithelium. The pathways involved in channel activation by β adrenergic agonists or cAMP are still under investigation but could involve changes in the intracellular chloride concentration and Ca2+ sensitivity of the channel.56 57

Na+-K+ATPase, which consists of two subunits, is another major component of the transepithelial Na+ transport system (fig 1). The α subunit is the catalytic component of the complex and is involved in Na+ extrusion, K+ intrusion and ATPase activity.36 The β subunit is a highly glycosylated protein whose role is not well understood but seems to be an important regulatory component of the sodium pump.56 57 60 α, β subunits have been detected in the lungs.59 61 Na+-K+ATPase inhibition with ouabain has been shown to greatly reduce solute transport in alveoli28 and short circuit the current of alveolar type II cells.62 Changes in intracellular Na+ concentration and various hormones such as mineralocorticoids, adrenergic agonists, and thyroid hormones have been found to modulate Na+-K+ATPase activity.59 62 Although these responses are thought to be mediated by direct protein phosphorylation by either PKA or protein kinase C (PKC), other possible mechanisms of regulation have been postulated (fig 1).58 62 Few studies have examined the regulation of expression in normal alveolar epithelial cells. In one investigation it was shown that β adrenergic agonists increase Na+-K+ATPase activity in alveolar type II cells.63 As with ENaC, heightened Na+-K+ATPase expression could also be an important tactic to augment transepithelial Na+ transport (fig 1). It is well known that Na+-K+ATPase expression is increased around birth.60 64 Many major hormonal systems such as the thyroid, mineralocorticoid, and glucocorticoid systems65 67 have been reported to modulate Na+-K+ATPase expression. In the lung the α subunit does not seem to be modulated by corticosteroids68 but the β subunit is.45 The β adrenergic system is also a potent stimulant of...
Na\(^+\)-K\(^-\)-ATPase expression in alveolar epithelial cells (fig 1).\(^{12}\)

Until recently it was generally accepted that liquid movement across the alveolar epithelium was an intercellular process secondary to the osmotic gradient generated by transepithelial Na\(^+\) transport across the alveolar epithelium. However, several laboratories have now demonstrated the presence of specialised water transport proteins in the lung, which could mean that water movement occurs not only through paracellular pathways but also through a transcellular route (fig 1).\(^{66}\) Although four different members of the family of aquaporins are expressed in lung tissue, aquaporin 5 is the predominant form expressed in alveolar type I cells.\(^{67}\) Since this cell type has one of the highest cellular permeability coefficients for water, it could be postulated that some water movement across the alveolar epithelium is across type I cells.\(^{68}\) In fact, experiments performed on the isolated perfused lung have confirmed that there is significant water movement across aquaporins in the lung.\(^{69,70}\) Although there is strong evidence to suggest that water channels are physiologically relevant proteins in the lung, we know very little about their regulation. What is clear is that their expression is changed around birth\(^{70}\) and that modulation of the phenotype of cultured type II cells by keratinocyte growth factor (KGF) can also alter the expression of aquaporin 5.\(^{67}\) However, much more information will be needed to determine the possible role of these proteins in the pathophysiology of pulmonary oedema.

**WHAT DO WE KNOW ABOUT OEDEMA CLEARANCE IN PATHOLOGICAL STATES?**

Although there is a substantial amount of evidence to support the concept that clearance of liquid from the lung is mediated by active Na\(^+\) transport, and several pathways could be stimulated to enhance its efficiency in the normal lung, we have to wonder if this system is functional in pathological conditions. Recently, a growing number of studies have shown that the process could be functional in a number of pathological states. Some investigations have evaluated the impact of lung injury on the integrity and function of the alveolar epithelium. Interestingly, the results indicate that alveolar and distal airway epithelia are remarkably resistant to injury, particularly in comparison with the adjacent lung endothelium.\(^{66}\) Even when mild to moderate alveolar epithelial injury occurs, the capacity of the alveolar epithelium to transport salt and water is often preserved. In addition, several mechanisms may result in upregulation of the fluid transport capacity of the distal pulmonary epithelium, even after moderate lung injury.\(^{71}\) One of the models used is the sepsis model.\(^{72}\) In sheep, intravenous *E coli* endotoxin produced a marked increase in vascular permeability but had no effect on epithelial permeability or on alveolar liquid clearance. In the septic rats, even though endothelial injury and mild interstitial pulmonary oedema occurred after intravenous administration of endotoxin, alveolar epithelial fluid transport was augmented by 32%.\(^{73}\) This enhanced liquid clearance was inhibited by instillation of amiloride (10\(^{-4}\) M) or propranolol (10\(^{-4}\) M) into the distal air spaces, demonstrating that increased clearance depended on \(\beta\) agonist stimulation of alveolar epithelial sodium transport. Since the septic shock induced in the rats was associated with a marked rise in plasma adrenaline (epinephrine) levels, it was concluded that endogenous release of catecholamines could possibly explain the enhanced liquid clearance observed. When more severe septic shock was produced in sheep, the alveolar epithelial barrier was resistant to injury in the majority of animals with oedema being confined to the pulmonary interstitium.\(^{74}\) In some sheep, however, more severe systemic and pulmonary endothelial injuries were associated with alveolar flooding, a striking rise in epithelial permeability to protein, and the inability to transport fluid from the air spaces of the lung.\(^{75}\) The inability to remove excess fluid from the air spaces in these sheep was probably related more to a marked increase in paracellular permeability from injury, but it is possible that this insult led to significant damage to the alveolar epithelium and, subsequently, to a loss of salt and water transport capacity of alveolar epithelial cells.\(^{75}\)

Interestingly, the expression and/or activity of ENaC and Na\(^-\)K\(^+\)-ATPase were upregulated in multiple models of lung injury. In a subacute model of hyperoxia (85% O\(_2\) for seven days) Sznajder et al\(^{76}\) were able to show an increase in active Na\(^+\) transport and lung liquid clearance at the end of the exposure period. Furthermore, this group of investigators has reported that enhanced Na\(^+\) transport is associated with augmented Na\(^-\)K\(^+\)-ATPase activity in the alveolar type II cells of these animals at the end of hyperoxic exposure.\(^{77}\) More recently Yue et al\(^{78}\) observed the increased expression and activity of sodium channels in alveolar type II cells of rats exposed to 85% O\(_2\) for seven days. Although these results suggest that Na\(^+\) transport mechanisms could be activated during hyperoxia induced lung injury, the proliferative response of alveolar type II cells seen in this model\(^{77}\) could also possibly explain such findings. Using a different model of lung injury (thiourea induced lung oedema) where there is no significant cell proliferation,\(^{79}\) we have also shown that lung Na\(^-\)K\(^+\)-ATPase activity is increased during recovery from lung injury.\(^{80}\) The activity of the enzyme reached its maximum at 12 hours, a time when we start to observe a decrease in the oedema content of the lung.\(^{79}\) This increased activity is also associated with an increased quantity of the enzyme in the lung and, more precisely, in alveolar type II cells at 12 hours.\(^{79}\) These results suggest that Na\(^+\) transport could be upregulated in lung injury.

However, other experimental data have suggested that the Na\(^+\) transport mechanism could be downregulated in severe lung injury. Firstly, it has recently been shown that inflammatory products such as reactive oxygen and nitrogen species can inhibit Na\(^+\) transport\(^{81}\) and Na\(^+\) channel activity.\(^{82}\) There are also conflicting
data regarding the modulation of the expression and activity of Na⁺-K⁺-ATPase in an acute model of hyperoxic lung injury where animals are exposed to 100% O₂ for 60 hours. Nici et al. demonstrated increased expression of Na⁺-K⁺-ATPase mRNA and protein in exposed animals compared with controls. The same group has shown that this adaptive response of Na⁺-K⁺-ATPase in alveolar type II cells is associated with enhanced active Na⁺ transport in vivo. However, Olivera et al. recently reported a decrease in active Na⁺ transport at the end of hyperoxic exposure but with an increase at seven days after exposure. The difference between these findings can possibly be explained by a heterogeneous response to injury. In fact, recent data show that the response of the alveolar epithelium to this type of damage is quite heterogeneous and that the impact on the Na⁺ transport mechanism also depends on the severity of the injury.

Collectively, these observations suggest that there could be significant activation of the Na⁺ transport mechanism in lung injury but this mechanism might not be functional when the alveolar epithelium is severely damaged.

HOW DO ALVEOLAR EPITHELIAL CELLS REPAIR INJURED AIR SPACES?

Although removal of oedema liquid is important in the resolution of ARDS, one of the most essential functions of the alveolar epithelium is participation in the repair of alveolar structures. Residual type II alveolar epithelial cells, which are more resistant to injury than type I alveolar epithelial cells, are the source of recovery for distal epithelia of the air spaces. The turnover rate of type II alveolar epithelial cells in the normal adult lung is remarkably low at about 4% per day but it is boosted after acute lung injury (ALI). However, proliferation of alveolar epithelial cells, which is the most obvious and easily measurable event leading to repair, needs several hours to take place and at least one or two days to be significant (fig 2). Clearly, adhesion, spreading and migration are prerequisites to optimal alveolar epithelial cell repair (fig 2).

To date there is very little evidence of spreading—migration of alveolar epithelial cells in the lung in vivo. This can be explained by the lack of sensitive and specific tools for studying epithelial cell migration in vivo and also by the difficulty in realizing real time observation of lung tissues in comparison with other tissues such as the skin, eyes and bowel.

There are at least two good reasons to consider migration-spreading-adhesion processes as being important for epithelial repair: (1) the increasing demonstration of early, efficient and sometimes sufficient locomotion and/or spreading of epithelial cells after tissue injury, and (2) recent in vitro and ex vivo reports of induced alveolar epithelial cell migration-spreading under controlled conditions without proliferation. It is reasonable to postulate that, depending on the type and extent of injury (as it occurs in ARDS), migration-spreading, which is the fastest inducible repairing event, can proceed to restore or prepare and set up alveolar epithelial cell restitution by proliferation, as already observed in other organs to be resurfaced.

Cell migration is a spatially and temporally integrated process with membrane extensions (for example, lamellipodia, filopodia), formation and stabilisation of cell substratum attachments, spreading of contractile forces and traction, coordination of rear release, and front edge progression. While this can take a couple of minutes for neutrophils or a couple of hours for fibroblasts, it needs a few hours to initiate but several hours to operate optimally (8–16 hours) for alveolar epithelial cells. Thus, it is likely that alveolar epithelial cell proliferation and migration overlap in some places, although there are arguments that both activities cannot coexist in the same cell. The two processes are complementary although each can be individually sufficient for wounding under specific conditions, with proliferation definitely being a powerful repair mechanism.

Adhesion, spreading, migration and proliferation also require communication of the cells with their environment. Epithelial cells will interact with either a provisional matrix rich in fibronectin, fibrinogen and plasma proteins containing multifold or fragmented remnants of basal membranes or with the extracellular matrix synthesised by the alveolar epithelial cells. Cell-matrix interactions are mediated by epithelial integrins through specific kinases such as pp125FAK (focal adhesion kinase) and I-LK (integrin-linked kinase). Normal wound healing especially induces the expression of α5β1 (fibronectin receptor), and α3β1 (laminin receptor) as well as uv heterodimerisation with β3, β5 and β6 (vitronectin receptors) to a lesser degree. Interestingly, hyaline charged alveolar epithelial cells in areas of early diffuse alveolar damage with intra-alveolar fibrosis fail to express basal α5β1 and exhibit dissociated actin-like microfilaments with a pattern of partial detachment from the alveolar walls.

In this respect epithelial cell shedding has been commonly observed for a long time in acute lung injury and chronic fibrosing alveolitis.
with a desquamative interstitial pneumonitis (DIP). Amongst TGF-β, IL-2 is an equivocal factor of LAEC migration but promoter when cells have been pre-exposed to IL-6, which suggests that it could perform a similar function in the lung and then prevent fibroblast overgrowth. Finally, TGF-α can stimulate alveolar epithelial cell wound closure in an in vitro model of alveolar type II cells.

The role of TGF-β in epithelial repair is complex and probably depends on the epithelium studied. Early after the induction of bleomycin lung injury there is a significant decrease in the secretion of biologically active TGF-β, which suggests that it could perform a similar function in the lung and then prevent fibroblast overgrowth. Finally, TGF-α can stimulate alveolar epithelial cell wound closure in an in vitro model of alveolar type II cells.

Table 1 Cytokines affecting growth and motility of lung alveolar epithelial cells

<table>
<thead>
<tr>
<th>Promoters</th>
<th>Growth</th>
<th>Inhibitors</th>
<th>Promoters</th>
<th>Migration</th>
<th>Inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td>EGF/TGF-α</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>Acetal FGF</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td></td>
</tr>
<tr>
<td>Basic FGF</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>IL-6</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>HGF</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>IL-1</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>PDGF</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>TGF-β</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>IFN-γ</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>IGF-I and II</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
</tbody>
</table>

*KGF is pro-migratory for lung alveolar epithelial cells (LAEC) seeded on a fibronectin matrix but not on a neutral gelatin matrix.

†IL-6 is an equivocal factor of LAEC growth and migration but inhibits TGF-β and EGF-induced LAEC migration on gelatin matrix.

‡IL-2 is an equivocal factor of LAEC migration but promoter when cells have been pre-exposed to IFN-γ.

Amongst TGF-β isomers only TGF-β is pro-migratory for LAEC.

§IFN-γ is an equivocal factor of LAEC migration but inhibits TGF-β and EGF-induced LAEC migration on gelatin matrix.

*Which cytokines are required for alveolar epithelial cell repair?

Both migration and proliferation need modulators (table 1). Nearly all cytokines identified recently as promoters of alveolar epithelial cell migration are heparin sulphate binding proteins—e.g. epithelial growth factor (EGF), transforming growth factor (TGF-α), keratinocyte growth factor (KGF), hepatocyte growth factor (HGF), fibroblast growth factor (FGF), KGF, HGF, and FGF are paracrine fibroblast derived polypeptides, while EGF and TGF-α can act in an autocrine-paracrine manner on alveolar epithelial cells bearing receptors. These heparin binding cytokines are now well recognised and are clearly omnipresent in the lung and during development and after lung injury, two processes that are associated with significant remodelling of the alveolar epithelium. KGF is a powerful promoter of proliferation and migration of alveolar epithelial cells and, when delivered locally, can reduce disease intensity and overall mortality in experimental models such as lung injury induced by acid, bleomycin, and hyperoxia. HGF can dramatically reverse Fas ligation induced fulminant hepatocyte apoptosis, which suggests that it could perform a similar function in the lung and then prevent fibroblast overgrowth. Finally, TGF-α can stimulate alveolar epithelial cell wound closure in an in vitro model of alveolar type II cells.

The role of TGF-β in epithelial repair is complex and probably depends on the epithelium studied. Early after the induction of bleomycin lung injury there is a significant decrease in the secretion of biologically active TGF-β, which suggests that it could perform a similar function in the lung and then prevent fibroblast overgrowth. Finally, TGF-α can stimulate alveolar epithelial cell wound closure in an in vitro model of alveolar type II cells.

Platelet-derived growth factor (PDGF) is an intriguing putative modulator for alveolar epithelial cell repair. PDGF-BB is present early in increased amounts in injured lungs and has long been designated a culprit in lung fibrogenesis. However, PDGF is also mitogenic for fetal alveolar epithelial cells. Since it can improve wound healing in the skin and gastric epithelial cell restoration, it would be interesting to study migration as well as proliferation of alveolar epithelial cells in the injured lung in response to PDGF.

Lymphomonokines IL-2, IL-15 and IFN-γ may play an unexpected role in epithelial restitution in ARDS. In this respect, IL-2 and the functionally related IL-15 have already been clearly identified as major factors involved in intestinal epithelial cell repair.

ARDS = acute respiratory distress syndrome

Figure 3 Failure in epithelial cell repair following acute lung injury. The failure of migration and proliferation of alveolar epithelial cells leads to shedding of epithelial cells and the development of fibrosis. ALI = acute lung injury; LAEC = lung alveolar epithelial cell.

Figure 3 Failure in epithelial cell repair following acute lung injury. The failure of migration and proliferation of alveolar epithelial cells leads to shedding of epithelial cells and the development of fibrosis. ALI = acute lung injury; LAEC = lung alveolar epithelial cell.

Table 1 Cytokines affecting growth and motility of lung alveolar epithelial cells

<table>
<thead>
<tr>
<th>Promoters</th>
<th>Growth</th>
<th>Inhibitors</th>
<th>Promoters</th>
<th>Migration</th>
<th>Inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td>EGF/TGF-α</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>Acetal FGF</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td></td>
</tr>
<tr>
<td>Basic FGF</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>IL-6</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>HGF</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>IL-1</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>PDGF</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>TGF-β</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>IFN-γ</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>IGF-I and II</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
</tbody>
</table>

*KGF is pro-migratory for lung alveolar epithelial cells (LAEC) seeded on a fibronectin matrix but not on a neutral gelatin matrix.

†IL-6 is an equivocal factor of LAEC growth and migration but inhibits TGF-β and EGF-induced LAEC migration on gelatin matrix.

‡IL-2 is an equivocal factor of LAEC migration but promoter when cells have been pre-exposed to IFN-γ.

Amongst TGF-β isomers only TGF-β is pro-migratory for LAEC.

§IFN-γ is an equivocal factor of LAEC migration but inhibits TGF-β and EGF-induced LAEC migration on gelatin matrix.

*Which cytokines are required for alveolar epithelial cell repair?

Both migration and proliferation need modulators (table 1). Nearly all cytokines identified recently as promoters of alveolar epithelial cell migration are heparin sulphate binding proteins—e.g. epithelial growth factor (EGF), transforming growth factor (TGF-α), keratinocyte growth factor (KGF), hepatocyte growth factor (HGF), fibroblast growth factor (FGF), KGF, HGF, and FGF are paracrine fibroblast derived polypeptides, while EGF and TGF-α can act in an autocrine-paracrine manner on alveolar epithelial cells bearing receptors. These heparin binding cytokines are now well recognised and are clearly omnipresent in the lung and during development and after lung injury, two processes that are associated with significant remodelling of the alveolar epithelium. KGF is a powerful promoter of proliferation and migration of alveolar epithelial cells and, when delivered locally, can reduce disease intensity and overall mortality in experimental models such as lung injury induced by acid, bleomycin, and hyperoxia. HGF can dramatically reverse Fas ligation induced fulminant hepatocyte apoptosis, which suggests that it could perform a similar function in the lung and then prevent fibroblast overgrowth. Finally, TGF-α can stimulate alveolar epithelial cell wound closure in an in vitro model of alveolar type II cells.

The role of TGF-β in epithelial repair is complex and probably depends on the epithelium studied. Early after the induction of bleomycin lung injury there is a significant decrease in the secretion of biologically active TGF-β, which suggests that it could perform a similar function in the lung and then prevent fibroblast overgrowth. Finally, TGF-α can stimulate alveolar epithelial cell wound closure in an in vitro model of alveolar type II cells.

Platelet-derived growth factor (PDGF) is an intriguing putative modulator for alveolar epithelial cell repair. PDGF-BB is present early in increased amounts in injured lungs and has long been designated a culprit in lung fibrogenesis. However, PDGF is also mitogenic for fetal alveolar epithelial cells. Since it can improve wound healing in the skin and gastric epithelial cell restoration, it would be interesting to study migration as well as proliferation of alveolar epithelial cells in the injured lung in response to PDGF.

Lymphomonokines IL-2, IL-15 and IFN-γ may play an unexpected role in epithelial restitution in ARDS. In this respect, IL-2 and the functionally related IL-15 have already been clearly identified as major factors involved in intestinal epithelial cell repair.
also known to decrease keratinocyte migration and alveolar epithelial cell growth and locomotion.119,120 On the other hand, IFN-γ increases IL-2R expression on alveolar epithelial cells115 and promotes IL-2 induced alveolar epithelial cell growth activity.118,119 While IL-2 and IL-15 are already recognised protectors against lymphocyte and neutrophil apoptosis,120,121 IL-15 can also dramatically reverse fulminant hepatocyte apoptosis122 and could exert similar anti-apoptotic protection in alveolar epithelial cells.

**Rescue therapy of the alveolar epithelium**

Since the alveolar epithelium is so important for lung function, and based on the knowledge acquired over the past few years, we can imagine therapeutic approaches aimed at the alveolar epithelium that could accelerate recovery from ARDS.

**STRATEGIES TO ACCELERATE OEDEMA CLEARANCE**

Even if active Na+ transport is involved in the resolution of pulmonary oedema, could we stimulate it to enhance oedema resolution? In one clinical study of patients with lung injury it was shown that about 40% of subjects were able to reabsorb some of the alveolar oedema fluid within 12 hours of intubation.7 These patients recovered more rapidly from respiratory failure and also had lower mortality. In contrast, patients who did not reabsorb any alveolar oedema fluid in the first 12 hours after acute lung injury had protracted respiratory failure and higher mortality.8 Based on clinical studies, the ability of the alveolar epithelial barrier to reabsorb alveolar oedema fluid within the first 12 hours after acute lung injury is preserved in 30–40% of patients.7 The results suggest that pharmacological manipulation of the alveolar epithelium could possibly accelerate the resolution of pulmonary oedema in zones where it is intact. In other areas of the lung, where significant injury to the alveolar epithelium has occurred, reconstitution will be necessary before this process can be modulated. Finally, in areas of intense alveolar type II cell proliferation it is possible that there would be intrinsic enhanced alveolar liquid clearance (fig 4).141

What are the pharmacological agents that could be used to stimulate clearance of lung liquid in patients with an intact alveolar epithelium? The agents most studied at the moment in animal models have been the β adrenergic agonists which can stimulate clearance of lung liquid in several species123–125,126 including the ex vivo human lung.127,128 This effect of the β adrenergic agonists can be obtained either by intra-alveolar or intravenous administration.129

More recently it was also shown that aerosolised salmeterol, a lipid soluble β agonist, can stimulate clearance of lung liquid at a clinically relevant dose.130

Not only can the β adrenergic agonist stimulate clearance of lung liquid in the normal lung, but it can also accelerate liquid clearance in the presence of hyperoxic lung injury. Lasnier et al131 reported that terbutaline (10⁻⁵ M) increased alveolar liquid clearance by 50% in rats exposed to 100% oxygen for 60 hours. Similarly, Garat et al132 noted that alveolar liquid clearance was enhanced by 45% in animals treated with terbutaline (10⁻⁵ M) after 40 hours exposure to 100% oxygen. Furthermore, the β adrenergic agonist not only modulates the Na⁺ channel or Na⁺-K⁺-ATPase activity involved in this response, but it can also alter the expression or quantity of these proteins (fig 2). In fact, some recent studies have shown that the sustained treatment of alveolar type II cells with β adrenergic agonists can increase the expression of ENaC and Na⁺-K⁺-ATPase.133 Thus, it is possible that sustained treatment with β adrenergic agonists could play a part in the management of patients with lung injury. Furthermore, other vasoactive agents commonly used in patients in the intensive care unit could have therapeutic applications—for example, dobutamine134 and dopamine135 have recently been shown to upregulate alveolar liquid clearance.

However, controlled clinical trials will be needed to evaluate these potential treatments since clinical conditions in which they would be used could vary significantly from one patient to another, and this could have significant repercussions on their efficacy. As we have already discussed, mild septic shock is associated with an increase in lung liquid clearance secondary to the endogenous release of catecholamines.136 However, more severe sepsis is accompanied by significant dysfunction of the alveolar epithelium, preventing proper modulation of lung liquid clearance.137 Furthermore, recent work has indicated that, after prolonged haemorrhagic shock in rats, oxidant mechanisms downregulate the response of the alveolar epithelium to β agonist stimulation.138 Hence, it is unlikely that in severe lung injury the use of β adrenergic agonists or vasoactive agents will be effective as a single therapy for rescue of the alveolar epithelium. Finally, as has already been shown in septic rats, there is an endogenous response to this stress by the release of endogenous catecholamines...
it is still uncertain if exogenous β adrenergic agents given under such circumstances would add to the endogenous release. Clearly, the idea of therapeutically modulating the alveolar epithelium to enhance liquid clearance is feasible, but many obstacles remain to be overcome before the concept can be tested at the bedside.

STRATEGIES TO ACCELERATE EPITHELIAL REPAIR

Although multiple cytokines have been shown to be important in repair of the alveolar epithelium, few studies have been done to evaluate their potential in the treatment of lung injury. Recent animal experiments indicate that HGF and KGF could have a significant role as new therapeutic agents. Administration of HGF to animals with lung injury can stimulate alveolar epithelial cell proliferation.149 Furthermore, pretreatment of rats with KGF (5 mg/kg) prior to lung injury induced by thiourea, bleomycin or hyperoxia leads to a decrease in the severity of lung injury.118–120 However, it is still unclear if this protective effect of KGF is linked to its impact on the proliferation of alveolar epithelial cells. In fact, KGF is not only known to modulate the phenotypic characteristic of alveolar epithelial cells157 but is also able to increase Na–K–ATPase expression and up-regulate Na+ transport in cultured alveolar type II cells.150 Furthermore, in vivo experiments performed recently to explore the mechanism responsible for this response suggest that the protective effect of KGF includes not only the heightened proliferation of alveolar type II cells but also the upregulation of Na+ transport across the alveolar epithelium.151 The potential value of manipulating therapeutically other growth factors such as TGF-α or TGF-β in lung injury has not yet been evaluated.

Although growth factors could have some therapeutic potential in ARDS, much work is needed to define better their therapeutic value since manipulation of this system could also have a negative impact. In fact, it is known that overexpression of certain growth factors could lead to pulmonary fibrosis. Indeed, transgenic mice overexpressing TGF-α develop pulmonary fibrosis.152 Thus, as with the development of therapeutic strategies for enhancing oedema clearance, strategies to promote epithelial repair are still in their embryonic stage of development.

Conclusion

Treatment of ARDS at the moment remains largely supportive since none of the therapies evaluated has been shown to reduce morbidity or mortality in controlled clinical trials. Nevertheless, in recent years standard supportive therapies seem to have led to a significant decrease in mortality. A further fall in mortality from ARDS should evolve from a better understanding of the causes of death in patients with ARDS.

Since the major causes of death in ARDS have been shown to be non-pulmonary organ dysfunction,1 it is relevant to wonder why a treatment aimed at the alveolar epithelium would help these patients. Although the major source of mortality is non-pulmonary organ dysfunction, it is possible that lung dysfunction could be significantly implicated in this process. In fact, pulmonary dysfunction leads to significant alterations in gas exchange which necessitate mechanical ventilation. There is an increasing amount of evidence that mechanical ventilation of the injured lung133 not only causes further injury but also induces a systemic inflammatory response that could be important for the development of non-pulmonary organ dysfunction.154 Acceleration of oedema clearance and repair of the alveolar epithelium should enhance the resolution of respiratory failure and decrease the time patients have to be on mechanical ventilation. A combination of treatments aimed at the control of the inflammatory response and at the restitution of normal epithelial function should lead eventually to a fall in the mortality of patients with ARDS.

This work was supported in part by The Medical Research Council of Canada (grant MT-1203). Dr Berthiaume and Dr Lesur are Chercheur-Boursier clinicians from Fonds de la Recherche en Santé du Québec.

17 Adamson IY, Bowden DH. The type 2 cell as progenitor of alveolar epithelial regeneration. A cytodynamic study in mice after exposure to oxygen. Lab Invest 1975;33:35–42.
Treatment of adult respiratory distress syndrome


Treatment of adult respiratory distress syndrome: plea for rescue therapy of the alveolar epithelium
Yves Berthiaume, Olivier Lesur and André Dagenais

Thorax 1999 54: 150-160
doi: 10.1136/thx.54.2.150

Updated information and services can be found at:
http://thorax.bmj.com/content/54/2/150

These include:

References
This article cites 126 articles, 59 of which you can access for free at:
http://thorax.bmj.com/content/54/2/150#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Adult respiratory distress syndrome (111)
Epidemiologic studies (1829)
Inflammation (1020)
Interstitial lung disease (559)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/